I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISTH 2024

-
Coming soon
06:45 AM
Duration 15mins Ballroom B2
Long-term follow-up of participants in the Phase I/II trial of dirloctocogene samoparvovec (SPK-8011): durable FVIII expression and clinically meaningful reduction of bleeding
George L, Croteau SE, Chang T, Eyster ME, Tran H, Ragni MV, Sullivan S, Rasko JEJ, Moormeier J, Angchaisuksiri P, Teitel J, Kenet G, Wynn T, Samelson-Jones B, Jaeger S, Ramos J, Mingozzi F, Levy G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:45 AM
Duration 60mins Bangkok, Thailand
Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry
Poon MC, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino D, Iorio A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
Relationship between current and historic clinical characteristics and bleeding outcomes in people with severe haemophilia A on emicizumab without recent FVIII inhibitors: a multivariate analysis of data from the CHESS studies
Polito L, Oellerich M, Chafaie R, Burke T, Blenkiron T, Ferri Grazzi E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
Hemoglobin improvement among patients with hemophilia A treated with emicizumab prophylaxis: post hoc analysis of the HAVEN 1, 3, 4 and STASEY trials
Batsuli G, Gupta S, Tzeng E, Gao L, Lim E, Sidonio Jr R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
Long-term safety and effectiveness of emicizumab in people with hemophilia A in the Hemophilia Natural History Study (ATHN 7)
Recht M, Carpenter SL, Lee L, Mclean TW, Morton P, Staber JM, Wang M, Chrisentery-Singleton T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
Emicizumab and females with hemophilia A in the ATHNdataset and prospective ATHN 7 study
Chrisentery-Singleton T, Lee L, Morton P, Recht M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
NXT007, a novel bispecific antibody, in factor VIII chromogenic substrate assays
Kiialainen A, Bektic L, Schmitt C, Hart D, David T, Chen D, Locke M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Bangkok, Thailand
Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics
Ranta S, Lassila R, Westesson LM, Quere S, Hoffmann M, Castro Sanchez AY, Czirok T, Holme PA, Astermark J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar